Publicacións (28) Publicacións nas que participase algún/ha investigador/a

filter_list Internal Medicine

2025

  1. Risk of Malignancy Related to Ixekizumab in Patients with Psoriatic Arthritis or Axial Spondyloarthropathy: Systematic Review and Meta-analysis

    Journal of Clinical Rheumatology, Vol. 31, Núm. 2, pp. 53-59

2023

  1. Assessment of anti-malondialdehyde-acetaldehyde antibody frequencies in rheumatoid arthritis with new data from two independent cohorts, meta-analysis, and meta-regression

    Arthritis Research and Therapy, Vol. 25, Núm. 1

2022

  1. Antibodies against 4 Atypical Post-Translational Protein Modifications in Patients with Rheumatoid Arthritis

    Diagnostics, Vol. 12, Núm. 2

2021

  1. Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome

    Scientific Reports, Vol. 11, Núm. 1

2020

  1. A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis

    Scientific Reports, Vol. 10, Núm. 1

  2. All-trans retinoic acid inhibits migration and invasiveness of rheumatoid fibroblast-like synoviocytes

    Journal of Pharmacology and Experimental Therapeutics, Vol. 372, Núm. 2, pp. 185-192

  3. Association of serum anti-centromere protein F antibodies with clinical response to infliximab in patients with rheumatoid arthritis: A prospective study

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 5, pp. 1101-1108

  4. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 12, pp. 1544-1549

  5. Influence of MUC5B gene on antisynthetase syndrome

    Scientific Reports, Vol. 10, Núm. 1

  6. Levels of the novel endogenous antagonist of ghrelin receptor, liver-enriched antimicrobial peptide-2, in patients with rheumatoid arthritis

    Nutrients, Vol. 12, Núm. 4

2019

  1. Adipokines: Linking metabolic syndrome, the immune system, and arthritic diseases

    Biochemical Pharmacology, Vol. 165, pp. 196-206

2018

  1. E74-Like Factor (ELF3) and Leptin, a Novel Loop between Obesity and Inflammation Perpetuating a Pro-Catabolic State in Cartilage

    Cellular Physiology and Biochemistry, Vol. 45, Núm. 6, pp. 2401-2410

  2. Uncovering Cellular retinoic acid-binding protein 2 as a potential target for rheumatoid arthritis synovial hyperplasia

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Progranulin as a biomarker and potential therapeutic agent

    Drug Discovery Today, Vol. 22, Núm. 10, pp. 1557-1564

2016

  1. Pollutants make rheumatic diseases worse: Facts on polychlorinated biphenyls (PCBs) exposure and rheumatic diseases

    Life Sciences, Vol. 157, pp. 140-144

  2. Specific premature epigenetic aging of cartilage in osteoarthritis

    Aging, Vol. 8, Núm. 9, pp. 2222-2231

2015

  1. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: A systematic review and meta-analysis

    Arthritis and Rheumatology, Vol. 67, Núm. 1, pp. 117-127

  2. Predictors of treatment failure and mortality in native septic arthritis

    Clinical Rheumatology, Vol. 34, Núm. 11, pp. 1961-1967

  3. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients

    Seminars in Arthritis and Rheumatism, Vol. 44, Núm. 6, pp. 717-723

2012

  1. Lysophosphatidic acid receptor 1 suppression sensitizes rheumatoid fibroblast-like synoviocytes to tumor necrosis factor-induced apoptosis

    Arthritis and Rheumatism, Vol. 64, Núm. 8, pp. 2460-2470